Stevee Krognes News Today

Crestline Management LP lowered its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 5.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 5,660,732 shares of the company’s stock after selling 300,000 shares during the period. Denali Therapeutics makes up 10.3% of Crestline Management LP’s holdings, making the stock its biggest position. […]

Edmond DE Rothschild Holding S.A. grew its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 65.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 165,680 shares of the company’s stock after buying an additional 65,800 shares during the […]

Pier 88 Investment Partners LLC cut its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 10.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 45,240 shares of the company’s stock after selling 5,460 shares during the period. Pier 88 Investment Partners LLC’s […]

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $14.56 and last traded at $14.79, with a volume of 172121 shares changing hands. The stock had previously closed at $15.56. Analyst Ratings Changes DNLI has been the […]

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $14.56 and last traded at $14.79, with a volume of 172121 shares changing hands. The stock had previously closed at $15.56. Analyst Ratings Changes DNLI has been the […]

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its price objective dropped by analysts at UBS Group from $70.00 to $32.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s price objective suggests a potential upside of 65.29% from […]

Profund Advisors LLC lowered its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 13.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,154 shares of the company’s stock after selling 6,321 shares during the quarter. Profund Advisors LLC’s holdings in Denali Therapeutics […]

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) Director Steve E. Krognes sold 2,750 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total value of $47,547.50. Following the completion of the transaction, the director now directly owns 139,841 shares […]

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) Director Steve E. Krognes sold 3,208 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $19.43, for a total transaction of $62,331.44. Following the transaction, the director now directly owns 142,591 shares in the company, […]

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have earned a consensus rating of “Buy” from the thirteen analysts that are covering the company, MarketBeat.com reports. Thirteen equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued ratings on the stock […]